Drug intelligence / Profile preview

acetylsalicylic acid + metformin

Development stage: Preclinical
Lead developer: Laboratorios Silanes S.A. de C.V.
Modality: Small Molecules
Administration: Oral

Overview

A fixed-dose combination (FDC) of acetylsalicylic acid (aspirin) and metformin. This combination brings together metformin's antidiabetic properties with acetylsalicylic acid's antiplatelet and anti-inflammatory effects. The combination has shown potential benefits for patients with diabetes who have increased cardiovascular risk, and may have applications in cancer treatment and inflammatory diseases through synergistic effects on multiple signaling pathways including AMPK, NFκB, and STAT3.

Other names: aspirin + metformin

Targets

AMPK (Adenosine monophosphate–activated protein kinase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on acetylsalicylic acid + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetylsalicylic acid + metformin.

Explore the full profile